G 蛋白偶联受体（GPCRs）是药物研发的重要靶点，但信号转导复杂阻碍了药物开发。研究人员探索了 GPCRs 的偏向性信号传导和细胞内调节剂，发现其在精准医学中具有潜在应用价值，有助于开发更安全有效的药物。 在生命科学和医学领域，药物研发一直是攻克 ...

在人体中，46 种趋化因子（chemokine）与 23 种 G 蛋白偶联受体（GPCR）的相互作用协调细胞迁移，但其选择性和 promiscuity 的分子机制不明。研究人员通过整合多种数据，明确了相关识别元件。这有助于设计新型免疫疗法和细胞疗法，为相关疾病治疗提供新思路。

“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...

Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced ...

(NASDA SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...

Addex Therapeutics partner Indivior advances GABAB positive allosteric modulator programme successfully through IND enabling studies: Geneva, Switzerland Tuesday, May 13, 2025, 15 ...